Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of cd40

Nature Medicine

Volumn 5, Issue 7, 1999, Pages 780-787

  Sotomayor, Eduardo M ^a   Borrello, Ivan ^a   Tubb, Erev ^a   Rattis, Frédérique Marie ^a   Bien, Harold ^a   Lu, Zhengbin ^a   Fein, Steve ^a   Schoenberger, Stephen ^b   Levitsky, Hyam I ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD40 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY REACTION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; HELPER CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD40; CANCER VACCINES; CARCINOMA, RENAL CELL; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; IMMUNE TOLERANCE; KIDNEY NEOPLASMS; LUNG NEOPLASMS; LYMPHOCYTE TRANSFUSION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0032984347     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/10503     Document Type: Article

References (48)

1. Hung, K. et al. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188, 2357-2368 (1998).
2. Topalian, S.L. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr. Opin. Immunol. 6, 741-745 (1994).
3. Keene, J.A. & Forman, J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155, 768-782 (1982).
4. Kalams, S.A. & Walker, B.D. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188, 2199-2204 (1998).
5. Levitsky, H.I., Lazenby, A., Hayashi, R.J. & Pardoll, D.M. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J. Exp. Med. 179, 1215-1224 (1994).
6. Staveley-O' Carroll, K. et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95, 1178-1183 (1998).
7. Sotomayor, E.M., Borrello, I. & Levitsky, H.I. Tolerance and cancer: a critical issue in tumor immunology. Crit. Rev. Oncog. 7, 433-456 (1996).
8. Heath, W.R., Kurts, C., Miller, J.F. & Carbone, F.R. Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J. Exp. Med. 187, 1549-1553 (1998).
9. Grewal, I.S. & Flavell, R.A. A central role of CD40 ligand in the regulation of CD4+ T-cell responses. Immunol. Today 17, 410-414 (1996).
10. Noelle, R.J. CD40 and its ligand in host defense. Immunity 4, 415-419 (1996).
11. Kirberg, J. et al. Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J. Exp. Med. 180, 25-34 (1994).
12. Rolink, A., Melchers, F. & Andersson, J. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity 5, 319-330 (1996).
13. Constant, S. et al. Are primed CD4+ T lymphocytes different from unprimed cells? Eur. J. Immunol. 24, 1073-1079 (1994).
14. Braesch-Andersen, S. et al. Biochemical characteristics and partial amino acid sequence of the receptor-like human B cell and carcinoma antigen CDw40. J. Immunol. 142, 562-567 (1989).
15. Stamenkovic, I., Clark, E.A. & Seed, B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J. 8, 1403-1410 (1989).
16. van den Oord, J.J. et al. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am. J. Pathol. 149, 1953-1961 (1996).
17. Pammer, J., Weninger, W., Mazal, P.R., Horvat, R. & Tschachler, E. Expression of the CD40 antigen on normal endothelial cells and in benign and malignant tumours of vascular origin. Histopathology 29, 517-524 (1996).
18. Viac, J., Schmitt, D. & Claudy, A. CD40 expression in epidermal tumors. Anticancer Res. 17, 569-572 (1997).
19. Kluth, B. et al. Endothelial expression of CD40 in renal cell carcinoma. Cancer Res. 57, 891-899 (1997).
20. Jakobson, E., Jonsson, G., Bjorck, P. & Paulie, S. Stimulation of CD40 in human bladder carcinoma cells inhibits anti-Fas/APO-1 (CD95)-induced apoptosis. Int. J. Cancer 77, 849-853 (1998).
21. Kearney, E.R., Pape, K.A., Loh, D.Y. & Jenkins, M.K. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1, 327-339 (1994).
22. Pape, K.A., Merica, R., Mondino, A., Khoruts, A. & Jenkins, M.K. Direct evidence that functionally impaired CD4+ T cells persist in vivo following induction of peripheral tolerance. J. Immunol. 160, 4719-4729 (1998).
23. Kurts, C., Kosaka, H., Carbone, F.R., Miller, J.F. & Heath, W.R. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J. Exp. Med. 186, 239-245 (1997).
24. Kurts, C. et al. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184, 923-930 (1996).
25. Adler, A.J. et al. CD4(+) T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J. Exp. Med. 187, 1555-1564 (1998).
26. Lanzavecchia, A. Immunology. Licence to kill. Nature 393, 413-414 (1998).
27. Banchereau, J. & Steinman, R.M. Dendritic cells and the control of immunity. Nature 392, 245-252 (1998).
28. Albert, M.L., Sauter, B. & Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89 (1998).
29. Inaba, K. et al. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J. Exp. Med. 186, 665-672 (1997).
30. Fuchs, E.J. & Matzinger, P. Is cancer dangerous to the immune system? Semin. Immunol. 8, 271-280 (1996).
31. Medzhitov, R. & Janeway, C.A., Jr. Innate immune recognition and control of adaptive immune responses. Semin. Immunol. 10, 351-353 (1998).
32. Janeway, C.A., Jr. How the immune system recognizes invaders. Sci. Am. 269, 72-79 (1993).
33. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994).
34. Ridge, J.P., Di Rosa, F. & Matzinger, P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393, 474-478 (1998).
35. Schoenberger, S.P., Toes, R.E., van der Voort, E.I., Offringa, R. & Melief, C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393, 480-483 (1998).
36. Bennett, S.R. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478-480 (1998).
37. Guerder, S. & Matzinger, P. Activation versus tolerance: a decision made by T helper cells. Cold Spring Harb. Symp. Quant. Biol. 54, 799-805 (1989).
38. Kurts, C. et al. CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J. Exp. Med. 186, 2057-2062 (1997).
39. Lane, P., Haller, C. & McConnell, F. Evidence that induction of tolerance in vivo involves active signaling via a B7 ligand-dependent mechanism: CTLA4-lg protects V beta 8+ T cells from tolerance induction by the superantigen staphylococcal enterotoxin B. Eur. J. Immunol. 26, 858-862 (1996).
40. Van Parijs, L., Ibraghimov, A. & Abbas, A.K. The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity 4, 321-328 (1996).
41. Lanoue, A., Bona, C., von Boehmer, H. & Sarukhan, A. Conditions that induce tolerance in mature CD4+ T cells. J. Exp. Med. 185, 405-414 (1997).
42. Bogen, B. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur. J. Immunol. 26, 2671-2679 (1996).
43. Lo, D. et al. Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells. Eur. J. Immunol. 22, 1013-1022 (1992).
44. Verhasselt, V. et al. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. J. Immunol. 158, 2919-2925 (1997).
45. Bowen, F., Haluskey, J. & Quill, H. Altered C040 ligand induction in tolerant T lymphocytes. Eur. J. Immunol. 25, 2830-2834 (1995).
46. Ferlin, W.G. et al. The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 mAb. Eur. J. Immunol. 28, 525-531 (1998).
47. Dullforce, P., Sutton, D.C. & Heath, A.W. Enhancement of T cell-independent immune responses in vivo by CD40 antibodies. Nature Med. 4, 88-91 (1998).
48. Morgan, D.J. et al. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160, 643-651 (1998).